May 12, 2026
A new study suggests that GLP-1 receptor agonists do not affect muscle mass any more than weight loss caused by caloric restriction, and this appears to be true for strength as well [1]. What do we lose when we lose weight? GLP-1-based drugs, such as semaglutide and tirzepatide, have transformed obesity treatment. People on these...
March 02, 2022
An advance online preprint was recently released in Circulation Research examining carotid bodies' role in hypertension and diabetes [1]. It will be published in the journal later this week. Drugs that target the glucagon-like peptide 1 (GLP1) receptor are widely used to treat type 2 diabetes and have also been well-documented for their cardiovascular and...